Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Ovarian Cancer
What is your preferred approach to adjuvant treatment for stage IC grade 1 endometrioid ovarian adenocarcinoma?
Answer from: at Community Practice
Carbo/taxol x 6 Genetics
Sign In
or
Register
to read more
12838
Related Questions
Do you believe the collective data support neoadjuvant chemotherapy or primary debulking surgery for patients with advanced ovarian cancer?
How does your management and counseling of a patient with ovarian cancer change when they have significant persistent disease after neoadjuvant chemotherapy?
How do you logistically incorporate a "scope and score" of a patient with newly diagnosed advanced ovarian cancer into a busy OR schedule?
Does the PFS and OS data presented at ESMO 2025 for ENGOT-ov65/KEYNOTE-B96 (pembrolizumab + paclitaxel +/- bevacizumab) influence how you will incorporate IO therapy into platinum-resistant ovarian cancer?
Have you had patients who wish to take ivermectin and/or fenbendazole as adjunct treatments for gynecologic cancers, and if so, how have you handled this?
For an elderly woman with a platinum-resistant recurrence of a high-grade serous ovarian cancer who has been rendered NED surgically, is observation a reasonable approach?
What would be your radiation planning (boost technique and dose levels) for adjuvant treatment of endometrial cancer with high grade disease or aggressive histology if there was a positive margin at the parametrium after TAH+BSO. What influences your decision to include a cylinder brachytherapy boost versus parametrial boost alone with EBRT in this setting?
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
How will you treat an uterine embryonal rhabdomyosarcoma with regional node involvement resected to involved parametrial margins?
Does lymphovascular invasion trump POLE mutation in early-stage uterine cancer adjuvant therapy decisions?